Table 2: Detailed distributions of clinical and pathological characteristics between non-changes level group, decrease and increased TILs level groups.
Variable |
TILs changes between pre and post NAC |
X2 |
||
|
|
Increase |
Decreased |
No-changes |
|
|
Age < 40 y |
14 (52%) |
15 (57%) |
28 (56%) |
p.905 |
|
cTNM |
|
|
|
|
|
IIa |
9 (33.3%) |
8 (30.8%) |
9 (18%) |
p.014 |
|
IIb |
12 (44.4%) |
10 (38.5%) |
10 (20%) |
|
|
IIIa |
5 (18.5%) |
5 (19.2%) |
10 (20%) |
|
|
IIIb |
0 (0%) |
1 (3.8%) |
9 (18%) |
|
|
IIIc |
1 (3.7%) |
2 (7.7%) |
12 (24%) |
|
|
Histology |
|
|
|
|
|
Ductal |
17 (63%) |
13 (50%) |
29 (58%) |
p.098 |
|
Lobulillar |
10 (37%) |
13 (50%) |
33 (42%) |
|
|
No DCIS in biopsy |
16 (59.3%) |
18 (69.2%) |
37 (74%) |
p.795 |
|
Grade 3 |
9 (33.3%) |
6 (23.1%) |
12 (24%) |
p.451 |
|
No LVI in biopsy |
19 (70.4%) |
22 (84.6%) |
32 (78%) |
p.050 |
|
Ki67 < 50% |
2 (7.4%) |
4 (16%) |
8 (16.8%) |
p.610 |
|
Low TIL pre NAC |
28 (100%) |
20 (76.9%) |
49 (98%) |
p.014 |
|
Antracyclines + taxanes |
26 (96%%) |
23 (89%) |
46 (92%) |
p.565 |
|
ypTNM |
|
|
|
|
|
I |
11 (40.7%) |
11 (42.3%) |
15 (30%) |
p.384 |
|
IIa |
5 (18.5%) |
10 (38.5%) |
10 (20%) |
|
|
IIb |
5 (18.5%) |
1 (3.8%) |
6 (12%) |
|
|
IIIa |
5 (18.5%) |
3 (11.5%) |
13 (26%) |
|
|
IIIb |
0 (0%) |
0 (0%) |
1 (2%) |
|
|
IIIc |
1 (3.7%) |
1 (3.8%) |
5 (10%) |
|
|
Residual tumor |
|
|
|
|
|
Multifocal |
5 (18.5%) |
7 (26.9%) |
11 (22%) |
p.393 |
|
DCIS specimen |
4 (14.8%) |
5 (19.2%) |
9 (18%) |
p.864 |
|
Low TIL after NAC |
0 (0%) |
6 (23.1%) |
36 (72%) |
p.001 |
|
LVI specimen |
6 (22.2%) |
6 (23.1%) |
16 (32%) |
p.671 |
|
BCS |
15 (55.6%) |
13 (50%) |
15 (30%) |
p.050 |
|
Adjuvant RT |
23 (85.2%) |
21 (80.8%) |
48 (96%) |
p.112 |